Creation of New Businesses Through Patent Licensing
First written in FY2018. 2 of 3 entries say "Advanced", first in FY2021-Q3. Latest entry: FY2021.
2 other companies' latest entry also says "Advanced".
- FY2021AdvancedAnnual report
「FCDI and Lonza Walkersville, Inc., a global leader in the manufacture of GMP-grade iPS cells, have also entered into an agreement covering the expanded use of iPS cell-related technologies worldwide. Under the agreement, pharmaceutical companies can use the expertise and technologies of both companies to manufacture iPS cells.」
The patent and technology licensing initiative has progressed to an agreement between FCDI and Lonza covering the expanded use of iPS cell-related technologies worldwide. - FY2021-Q3AdvancedAnnual report
「In November 2020, FCDI began full-scale provision of therapeutic iPS cells and licensing of patents related to iPS cell production technology. As its first such transaction, it granted Lonza Walkersville, Inc. a non-exclusive, worldwide licence to use patents related to iPS cell production technology for the development of regenerative medicine products.」
The patent licensing business has progressed to an actual transaction under which Lonza was granted a worldwide, non-exclusive license to FCDI's iPS cell production technology. - FY2018First statedAnnual report
「The company has fully rolled out a patent licensing business that supports the creation of new businesses by making its patents available through intellectual property exchanges. As its first project, it signed an agreement with a company in Kanagawa Prefecture concerning patented technology for self-healing resin materials.」
The company has fully rolled out a licensing business that makes its patents available to external companies, and has signed its first patent agreement for self-healing resin materials.